LISATA THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $0 | — |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M | -$29.1M |
| Operating expenses | $18.4M | $23.4M | $25.7M | $57.6M | $29.1M |
| Cash from operations | -$15.9M | -$19.4M | -$20.0M | -$21.2M | -$22.2M |
| Capital expenditure | $28,000 | $0 | $0 | $285,000 | $60,000 |
| Free cash flow | -$16.0M | -$19.4M | -$20.0M | -$21.5M | -$22.3M |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M | $97.0M |
| Total liabilities | $3.1M | $5.7M | $6.8M | $6.7M | $5.0M |
Shares outstanding 9.1M · Free float 66.1%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.